한글목차

2024년에는 16개국에서 5,200만 명 이상의 HSV-2 감염자가 진단될 것으로 예상됩니다.

뉴클레오시드 아날로그 항바이러스제는 20년 이상 생식기 헤르페스 치료의 주류로 자리 잡았습니다. 생식기 헤르페스 파이프라인은 중후반기 개발 단계에 있는 제품 수가 제한되어 있으며, 3상 제품은 1개, 2상 제품은 4개에 불과합니다.

지난 10년간 미국은 전 세계 GH 임상시험의 50%에 가까운 임상시험이 미국에서 실시된 최고의 임상시험 실시 국가였습니다. 인수는 북미, 유럽, 아시아태평양에서 가장 많은 거래 형태였습니다.

이 보고서는 전 세계 성기 헤르페스 시장을 조사하여 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 출시 약제
• 작용기서별 개요
• 투여 경로별 개요
• 제품 프로파일과 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지 시간

제6장 파이프라인 약제 평가

• 중기에서 후기 단계 파이프라인 약제
• 개발 단계별 개요
• 작용기서별 개요
• 분자 유형별 개요
• 약제 고유의 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야와 적응증별 PTSR과 LoA

제7장 임상시험 평가

• 역사적 개요
• 상별 개요
• 상황별 개요
• 진행중 및 계획중인 시험의 상별 개요
• 가상 컴포넌트를 사용한 임상시험
• 지역적 개요
• 지역별 단일국 및 다국적 시험
• 상위 20개 스폰서와 상별 내역
• 상위 20개 스폰서 상황별 내역
• 엔드포인트 상황별 개요
• 인종 및 민족별 개요
• 등록 데이터
• 임상시험 사이트 상위 20개국
• 세계의 상위 20개 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

• 주요 시장 진출 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in genital herpes therapeutics.

• In 2024, more than 52 million diagnosed prevalent cases of HSV-2 infection are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for GH.
• Nucleoside analogue antiviral drugs have been the mainstay of GH treatment for over two decades.
• The GH pipeline has a limited number of products in mid-to late-stage development, with only one product in Phase III and four products in Phase II.
• In the last 10 years, the US has been the top country for trial sites, as it hosted nearly 50% of the sites for GH clinical trials conducted globally.
• Acquisitions were the most prevalent deal type in North America, Europe, and Asia-Pacific.

Scope

GlobalData's genital herpes: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the genital herpes market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global genital herpes market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer